07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Philanthropy with muscle

CureDuchenne Ventures' latest venture philanthropy funding project will fill a €5 million ($6.3 million) funding gap for Prosensa Holding N.V. (NASDAQ:RNA) as the biotech advances its pipeline of therapies for Duchenne muscular dystrophy. The project,...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Sarepta Therapeutics, University of Western Australia deal

The university granted Sarepta exclusive, worldwide rights to IP covering exon-skipping drug candidates for Duchenne muscular dystrophy (DMD). The university is eligible to receive up to $7.1 million in upfront and milestone payments, plus low...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

The DoD issued stop-work orders to Sarepta (formerly AVI BioPharma Inc. ) and Tekmira for their government-funded Ebola programs due to recently imposed funding constraints. The companies expect to receive notification from DoD by Sept....
07:00 , Jul 30, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Almirall S.A. (Madrid:ALM) gained €0.14 to €6.17 last week while Forest Laboratories Inc. (NYSE:FRX) lost $0.86 to $34.04 after the European Commission approved an MAA from Almirall and FDA approved an NDA from...
01:52 , Jul 25, 2012 |  BC Extra  |  Clinical News

Sarepta jumps on clinical outcome data for eteplirsen

Sarepta Therapeutics Inc. (NASDAQ:SRPT) jumped $5.06 (146%) to $8.52 on Tuesday after reporting that once-weekly 50 mg/kg IV eteplirsen led to significantly better clinical outcomes at week 36 compared with placebo as evaluated by a...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Financial News

Sarepta Therapeutics financial update

Sarepta implemented a 1-for-6 reverse stock split, changed its name from AVI BioPharma Inc. and began trading under the symbol "SRPT." Following the split, the company has about 22.6 million shares outstanding. Sarepta Therapeutics Inc....
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Financial News

AVI BioPharma financial update

AVI BioPharma received notice from NASDAQ indicating that the company is not in compliance with the $1 minimum bid price requirement for continued listing. The company has until Nov. 27 to regain compliance. AVI BioPharma...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Eteplirsen: Phase IIb data

The double-blind, U.S. Phase IIb Study 4658-US-201 trial in 12 patients aged 7-13 with DMD showed that once-weekly 30 mg/kg IV eteplirsen met the primary endpoint of increasing dystrophin-positive muscle fibers as a percentage of...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

AVI-6002: Phase I data

Additional data from 5 healthy volunteers in the sixth dose cohort of a double-blind, placebo-controlled Phase I trial showed that single doses of 9 mg/kg IV AVI-6002 led to no safety concerns or treatment-related changes...